Targeted Canine Osteoarthritis Pain Relief
Galliprant is a first-in-class prostaglandin receptor antagonist (PRA), a non-COX inhibiting NSAID.
How Galliprant® (grapiprant tablets) Works
See how Galliprant provides targeted pain relief, allowing you to treat canine osteoarthritis with confidence.
A Mode of Action Like No Other
Galliprant’s mode of action delivers safe and effective pain relief for canine OA. If used long-term, appropriate monitoring is recommended.
First-in-class prostaglandin receptor antagonist (PRA); a non-COX inhibiting NSAID that specifically targets the EP4 receptor1
Mode of action targets canine OA pain and inflammation while reducing the impact on GI, kidney and liver homeostasis1,2
Indication
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
PM-US-19-1927(3)